Neurology : Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review

Neurology: Rituximab as treatment Infectious Disease or anti-MuSK myasthenia gravis: Multicenter blinded prospective review is organized by the American Academy of Neurology (AAN). This Text-based CME Course will be held from Sep 05, 2017 - Sep 05, 2020. This Online CME Course has been recognized For a maximum of 0.75 AMA PRA Category 1 Credits.

Conference Objectives are :
At the conclusion of this article by Hehir et al, the attendees should be able to:
• Explain the most common sex and relative age for patients with anti-MUSK myasthenia gravis in study
• Specify what percentage of rituximab-treated patients in this study met the primary outcome
• Understand what secondary outcomes from rituximab treatment were met during this review

Additional details will be posted as soon as they are available.